首页 > 最新文献

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan最新文献

英文 中文
[Redox Biology Involved in the Toxicity of Enterohemorrhagic Escherichia coli Toxin SubAB]. [涉及肠出血性大肠杆菌毒素 SubAB 毒性的氧化还原生物学]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00162-4
Hiroyasu Tsutsuki, Tianli Zhang, Tomohiro Sawa

AB5 toxins of pathogenic bacteria enter host cells and utilize the retrograde trafficking pathway to translocate to the cytoplasm and exert its pathogenesis. Cholera toxin and Shiga toxin reach the endoplasmic reticulum (ER), and the A subunit undergoes redox regulation by ER proteins to become active fragments, which pass through the ER membrane and translocate to the cytoplasm. By acting on molecular targets in the cytoplasm, the normal function of host cells are disrupted, causing diseases. ER chaperone proteins such as protein disulfide isomerase (PDI) and binding immunoglobulin protein (BiP) induce conformational changes triggered by the reduction of disulfide bonds in the A subunit. This is thought to be dependent on cysteine thiol-mediated redox regulation, but the detailed mechanism remains unclear. On the other hand, subtilase cytotoxin (SubAB), produced by enterohemorrhagic Escherichia coli (EHEC), localizes to the ER without translocating to the cytoplasm and cleaves BiP as a substrate. Therefore, it is thought that ER stress-based cytotoxicity and intestinal bleeding occur without translocating to the cytoplasm. We reported that PDI is involved in BiP cleavage through SubAB localization to the ER. Like other AB5 toxins, this indicates the involvement of redox regulation via chaperone proteins in the ER, but also suggests that SubAB does not translocate to the cytoplasm because it cleaves BiP. Although there are few reports on the redox state of ER protein thiols, it is suggested that polysulfidation, which is discussed in this symposium, may be involved.

致病菌的 AB5 毒素进入宿主细胞后,利用逆行运输途径转运到细胞质,发挥致病作用。霍乱毒素和志贺毒素到达内质网(ER)后,A 亚基在 ER 蛋白的氧化还原调节下成为活性片段,穿过 ER 膜转运到细胞质。通过作用于细胞质中的分子靶点,宿主细胞的正常功能被破坏,从而引发疾病。ER伴侣蛋白(如蛋白质二硫异构酶(PDI)和结合免疫球蛋白(BiP))通过减少A亚基中的二硫键引发构象变化。这被认为依赖于半胱氨酸硫醇介导的氧化还原调节,但具体机制仍不清楚。另一方面,肠出血性大肠杆菌(EHEC)产生的亚铁酶细胞毒素(SubAB)会定位于ER,而不会转运到细胞质,并以BiP为底物进行裂解。因此,人们认为基于ER应激的细胞毒性和肠道出血是在没有转运到细胞质的情况下发生的。我们报告说,PDI 通过 SubAB 定位于 ER 参与了 BiP 的裂解。与其他 AB5 毒素一样,这表明ER 中的伴侣蛋白参与了氧化还原调节,但同时也表明 SubAB 不会转运到细胞质,因为它会裂解 BiP。尽管有关 ER 蛋白质硫醇氧化还原状态的报道很少,但有人认为可能与多硫化有关,这也是本次研讨会讨论的内容。
{"title":"[Redox Biology Involved in the Toxicity of Enterohemorrhagic Escherichia coli Toxin SubAB].","authors":"Hiroyasu Tsutsuki, Tianli Zhang, Tomohiro Sawa","doi":"10.1248/yakushi.23-00162-4","DOIUrl":"10.1248/yakushi.23-00162-4","url":null,"abstract":"<p><p>AB<sub>5</sub> toxins of pathogenic bacteria enter host cells and utilize the retrograde trafficking pathway to translocate to the cytoplasm and exert its pathogenesis. Cholera toxin and Shiga toxin reach the endoplasmic reticulum (ER), and the A subunit undergoes redox regulation by ER proteins to become active fragments, which pass through the ER membrane and translocate to the cytoplasm. By acting on molecular targets in the cytoplasm, the normal function of host cells are disrupted, causing diseases. ER chaperone proteins such as protein disulfide isomerase (PDI) and binding immunoglobulin protein (BiP) induce conformational changes triggered by the reduction of disulfide bonds in the A subunit. This is thought to be dependent on cysteine thiol-mediated redox regulation, but the detailed mechanism remains unclear. On the other hand, subtilase cytotoxin (SubAB), produced by enterohemorrhagic Escherichia coli (EHEC), localizes to the ER without translocating to the cytoplasm and cleaves BiP as a substrate. Therefore, it is thought that ER stress-based cytotoxicity and intestinal bleeding occur without translocating to the cytoplasm. We reported that PDI is involved in BiP cleavage through SubAB localization to the ER. Like other AB<sub>5</sub> toxins, this indicates the involvement of redox regulation via chaperone proteins in the ER, but also suggests that SubAB does not translocate to the cytoplasm because it cleaves BiP. Although there are few reports on the redox state of ER protein thiols, it is suggested that polysulfidation, which is discussed in this symposium, may be involved.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139088706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Japanese Code of Ethics for Pharmacists and Professionalism]. [日本药剂师职业道德守则]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00172-3
Atsushi Toyomi

In their role as providers of pharmaceutical products to society, pharmacists must demonstrate professionalism if they are to gain the trust of the community. The Japan Pharmaceutical Association has published the Pharmacist Platform in Japan and the Japanese Code of Ethics for Pharmacists; these resources provide clear guidelines for pharmacists and are an important component of the profession. Becoming a pharmacist involves joining a professional community and thereby pledging to accept a set of ethical standards. This concept of the pharmacy profession is shared by other countries, and the International Pharmaceutical Federation has indicated that professionalism is an issue that should be addressed in every country. This review introduces the Pharmacist Platform in Japan, the Japanese Code of Ethics for Pharmacists established by the Japan Pharmaceutical Association, and the background of each establishment.

药剂师作为社会药品的提供者,要想赢得社会的信任,就必须表现出专业精神。日本药剂师协会出版了《日本药剂师纲领》和《日本药剂师职业道德准则》;这些资源为药剂师提供了明确的指导方针,是药剂师职业的重要组成部分。要成为一名药剂师,就必须加入一个专业团体,从而承诺接受一套道德标准。药剂师职业的这一概念得到了其他国家的认同,国际药学联合会也表示,职业化是每个国家都应解决的问题。本综述介绍了日本的药剂师平台、日本药剂师协会制定的《日本药剂师职业道德准则》以及各机构的背景。
{"title":"[Japanese Code of Ethics for Pharmacists and Professionalism].","authors":"Atsushi Toyomi","doi":"10.1248/yakushi.23-00172-3","DOIUrl":"10.1248/yakushi.23-00172-3","url":null,"abstract":"<p><p>In their role as providers of pharmaceutical products to society, pharmacists must demonstrate professionalism if they are to gain the trust of the community. The Japan Pharmaceutical Association has published the Pharmacist Platform in Japan and the Japanese Code of Ethics for Pharmacists; these resources provide clear guidelines for pharmacists and are an important component of the profession. Becoming a pharmacist involves joining a professional community and thereby pledging to accept a set of ethical standards. This concept of the pharmacy profession is shared by other countries, and the International Pharmaceutical Federation has indicated that professionalism is an issue that should be addressed in every country. This review introduces the Pharmacist Platform in Japan, the Japanese Code of Ethics for Pharmacists established by the Japan Pharmaceutical Association, and the background of each establishment.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141200705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Chemical Species Change of Radionuclides by Microorganisms: Effects of Exudated Siderophores]. [微生物对放射性核素化学性质的改变:渗出苷元的影响]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00197-4
Toshihiko Ohnuki

Microbial exudates including siderophore, which changes chemical species of actinides and lanthanides. We have investigated effects of desferrioxamine B (DFOB; one of the siderophores) and siderophore-like organic molecules (SLOM) on the adsorption of lanthanides by microbial cells, aluminium oxide (Al2O3), and manganese (Mn) oxides. When DFOB was present, the distribution coefficients of cerium (Ce) were measured to be lower than those of neighboring elements of lanthanum (La) and praseodymium (Pr) (Negative anomaly of Ce adsorption). Even though initial oxidation state of Ce in the solution was III, that was changed to IV after the addition of DFOB, indicating that Ce(III) was oxidized by forming complex with DFOB. When lanthanides were adsorbed by biogenic Mn(IV) oxides, negative anomaly of Ce adsorption was observed in the sorption in alkaline solution. Ce(III) was oxidized to forme the complexes of Ce(IV) with SLOM in the solution. These results show that siderophore possesses high performance of oxidation of Ce(III) to Ce(IV) during association, affectiong the adsorption behavior of Ce. After Fukushima accident, radioactive Cs accumulation by Eleutherococcus sciadophylloides (Koshiabura) caused by the dissolution of Fe from soil around the roots, that was dominated by siderophore releasing microorganisms (SB). These SBs may enhance dissolution of iron (Fe) and uranium (U) phases in the nuclear fuel debris formed in the nuclear reactors in Fukushima Daiichi nuclear power plant. Thus, in the interaction between microorganisms and radionuclides, SLOMs discharged by microorganisms are deeply involved in the chemical state change of radionuclides.

微生物的渗出物包括嗜铁素,它能改变锕系元素和镧系元素的化学种类。我们研究了去铁胺 B(DFOB,嗜铁物之一)和类嗜铁物有机分子(SLOM)对微生物细胞、氧化铝(Al2O3)和锰(Mn)氧化物吸附镧系元素的影响。当 DFOB 存在时,铈(Ce)的分布系数低于邻近元素镧(La)和镨(Pr)的分布系数(铈吸附负反常)。尽管溶液中 Ce 的初始氧化态为 III,但加入 DFOB 后,氧化态变为 IV,表明 Ce(III)与 DFOB 形成络合物而被氧化。当镧系元素被生物锰(IV)氧化物吸附时,在碱性溶液中的吸附过程中出现了吸附 Ce 的负反常现象。在溶液中,Ce(III) 与 SLOM 氧化生成 Ce(IV) 的络合物。这些结果表明,苷元在结合过程中能将 Ce(III) 氧化成 Ce(IV),从而对 Ce 的吸附行为产生影响。福岛核事故发生后,由于根部周围土壤中铁的溶解,导致鹅掌楸(Koshiabura)体内放射性铯的积累。这些 SB 可能会促进福岛第一核电站核反应堆中形成的核燃料碎片中铁(Fe)和铀(U)相的溶解。因此,在微生物与放射性核素的相互作用中,微生物排出的SLOMs深度参与了放射性核素的化学状态变化。
{"title":"[Chemical Species Change of Radionuclides by Microorganisms: Effects of Exudated Siderophores].","authors":"Toshihiko Ohnuki","doi":"10.1248/yakushi.23-00197-4","DOIUrl":"10.1248/yakushi.23-00197-4","url":null,"abstract":"<p><p>Microbial exudates including siderophore, which changes chemical species of actinides and lanthanides. We have investigated effects of desferrioxamine B (DFOB; one of the siderophores) and siderophore-like organic molecules (SLOM) on the adsorption of lanthanides by microbial cells, aluminium oxide (Al<sub>2</sub>O<sub>3</sub>), and manganese (Mn) oxides. When DFOB was present, the distribution coefficients of cerium (Ce) were measured to be lower than those of neighboring elements of lanthanum (La) and praseodymium (Pr) (Negative anomaly of Ce adsorption). Even though initial oxidation state of Ce in the solution was III, that was changed to IV after the addition of DFOB, indicating that Ce(III) was oxidized by forming complex with DFOB. When lanthanides were adsorbed by biogenic Mn(IV) oxides, negative anomaly of Ce adsorption was observed in the sorption in alkaline solution. Ce(III) was oxidized to forme the complexes of Ce(IV) with SLOM in the solution. These results show that siderophore possesses high performance of oxidation of Ce(III) to Ce(IV) during association, affectiong the adsorption behavior of Ce. After Fukushima accident, radioactive Cs accumulation by Eleutherococcus sciadophylloides (Koshiabura) caused by the dissolution of Fe from soil around the roots, that was dominated by siderophore releasing microorganisms (SB). These SBs may enhance dissolution of iron (Fe) and uranium (U) phases in the nuclear fuel debris formed in the nuclear reactors in Fukushima Daiichi nuclear power plant. Thus, in the interaction between microorganisms and radionuclides, SLOMs discharged by microorganisms are deeply involved in the chemical state change of radionuclides.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141200646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Medical Professionalism as a Pivotal Goal in the Postgraduate Clinical Training]. [医学职业精神是研究生临床培训的关键目标]。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00172-2
Tsuguya Fukui

Postgraduate clinical training for physicians in Japan has been mandatory since 2004, with the provision that the system itself is to be revised every 5 years if necessary. Major revisions were implemented in 2020, involving the objectives, strategies, and evaluations of the clinical training program. Among the revisions was a section on professionalism in the first part of objectives. As one of the committee members involved in the process of this revision, I provide an explanation of the historical background, learning strategies, and assessment of professionalism in physician training.

日本自 2004 年起开始强制推行医生研究生临床培训制度,并规定必要时每 5 年对制度本身进行一次修订。2020 年实施了重大修订,涉及临床培训计划的目标、策略和评估。修订内容之一是在目标的第一部分增加了关于职业精神的章节。作为参与此次修订过程的委员会成员之一,我对医师培训中专业精神的历史背景、学习策略和评估进行了说明。
{"title":"[Medical Professionalism as a Pivotal Goal in the Postgraduate Clinical Training].","authors":"Tsuguya Fukui","doi":"10.1248/yakushi.23-00172-2","DOIUrl":"10.1248/yakushi.23-00172-2","url":null,"abstract":"<p><p>Postgraduate clinical training for physicians in Japan has been mandatory since 2004, with the provision that the system itself is to be revised every 5 years if necessary. Major revisions were implemented in 2020, involving the objectives, strategies, and evaluations of the clinical training program. Among the revisions was a section on professionalism in the first part of objectives. As one of the committee members involved in the process of this revision, I provide an explanation of the historical background, learning strategies, and assessment of professionalism in physician training.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141200708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilization and Issues Related to Discharge Medication Summaries from Hospital Pharmacies to Community Pharmacies. 从医院药房到社区药房出院用药摘要的使用情况和相关问题。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00214
Yuko Fukuda, Mayu Suzuki, Risa Ito, Junko Inaba, Tetsuji Kanemoto, Toshiyuki Sahara, Masahiko Tsujikawa, Mitsuko Onda

In 2020, the Japan Community Healthcare Organization (JCHO) Hoshigaoka Medical Center started providing information to community pharmacies about patients admitted to the acute care ward using discharge medication summaries (the summaries). We conducted an online self-recording survey of 149 pharmacies belonging to the Hirakata City Pharmacists Association to clarify the usability of the summaries, any related issues, and to further discuss future collaboration between hospitals and pharmacies. 46 pharmacies have received the summaries in the past, of which 44 pharmacies answered that they have utilized the summaries with patient instruction and prescription queries of doctors. However, two pharmacies responded they did not utilize the summaries, and the reasons were (a) the information was not timely and (b) patients whom the discharge medical summary was sent for did not come to the pharmacy. There were some requests regarding the summaries such as, "I would like to know what kind of information hospital pharmacists want from community pharmacists." Preference for sharing information other than the summaries (e.g., online tools) with hospital pharmacists was related to whether the pharmacy was providing home pharmaceutical visit services. The survey revealed that, in addition to the usability of the summaries, there are also events that prevent them from being utilized. Some of the challenges include the timing of sending the summaries, the accurate identification of the family pharmacy and the communication of follow-up after discharge from hospital. Collaborating with pharmacies providing home pharmaceutical visit services would be beneficial in creating new system of bidirectional information sharing.

2020 年,日本社区医疗机构(JCHO)星丘医疗中心开始利用出院用药摘要(摘要)向社区药房提供急诊病房住院患者的信息。我们对属于枚方市药剂师协会的 149 家药房进行了在线自我记录调查,以明确摘要的可用性和相关问题,并进一步讨论医院和药房之间的未来合作。46 家药房过去曾收到过摘要,其中 44 家药房回答说,他们曾利用摘要对患者进行指导和向医生询问处方。不过,有两家药房回答说他们没有使用过摘要,原因是:(a) 信息不及时;(b) 收到出院医疗摘要的病人没有来药房。有一些关于摘要的要求,如:"我想知道医院药剂师希望从社区药剂师那里得到什么样的信息"。与医院药剂师共享摘要以外的信息(如在线工具)的偏好与药房是否提供家庭药学访问服务有关。调查显示,除了摘要的可用性外,还有一些事件阻碍了摘要的使用。其中一些挑战包括发送摘要的时间、家庭药房的准确识别以及出院后的后续沟通。与提供家庭药房访问服务的药房合作将有利于创建新的双向信息共享系统。
{"title":"Utilization and Issues Related to Discharge Medication Summaries from Hospital Pharmacies to Community Pharmacies.","authors":"Yuko Fukuda, Mayu Suzuki, Risa Ito, Junko Inaba, Tetsuji Kanemoto, Toshiyuki Sahara, Masahiko Tsujikawa, Mitsuko Onda","doi":"10.1248/yakushi.23-00214","DOIUrl":"https://doi.org/10.1248/yakushi.23-00214","url":null,"abstract":"<p><p>In 2020, the Japan Community Healthcare Organization (JCHO) Hoshigaoka Medical Center started providing information to community pharmacies about patients admitted to the acute care ward using discharge medication summaries (the summaries). We conducted an online self-recording survey of 149 pharmacies belonging to the Hirakata City Pharmacists Association to clarify the usability of the summaries, any related issues, and to further discuss future collaboration between hospitals and pharmacies. 46 pharmacies have received the summaries in the past, of which 44 pharmacies answered that they have utilized the summaries with patient instruction and prescription queries of doctors. However, two pharmacies responded they did not utilize the summaries, and the reasons were (a) the information was not timely and (b) patients whom the discharge medical summary was sent for did not come to the pharmacy. There were some requests regarding the summaries such as, \"I would like to know what kind of information hospital pharmacists want from community pharmacists.\" Preference for sharing information other than the summaries (e.g., online tools) with hospital pharmacists was related to whether the pharmacy was providing home pharmaceutical visit services. The survey revealed that, in addition to the usability of the summaries, there are also events that prevent them from being utilized. Some of the challenges include the timing of sending the summaries, the accurate identification of the family pharmacy and the communication of follow-up after discharge from hospital. Collaborating with pharmacies providing home pharmaceutical visit services would be beneficial in creating new system of bidirectional information sharing.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Perioperative Docetaxel-induced Limb Edema on Health-related Quality of Life in Patients with Early-stage Breast Cancer: A Prospective Observational Study. 多西他赛诱发的围手术期肢体水肿对早期乳腺癌患者健康相关生活质量的影响:前瞻性观察研究
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00206
Kaori Matsumoto, Yoshihito Morimoto, Junichiro Wakatsuki, Daiki Sakuma, Keiko Mukouyama, Masayuki Inoue, Ayako Kimura, Iori Hirosawa, Kazuhiro Watanabe

Docetaxel (DTX) is a key drug used in perioperative chemotherapy for breast cancer. Edema is a known adverse effect of DTX, but its effect on health-related QOL (HRQOL) is unclear. In this study, we evaluated the effects of edema caused by administration of DTX on HRQOL in patients with early-stage breast cancer. We prospectively investigated patients diagnosed with early-stage breast cancer (stage I-III) who received 4 cycles of DTX as preoperative or postoperative chemotherapy between September 2021 and December 2022 at Yamanashi Prefectural Central Hospital. The circumference of each extremity was measured at each administration of DTX, and limb edema was evaluated by Common Terminology Criteria for Adverse Events version 5.0. HRQOL was evaluated using SF-12 version 2, which has a range of 0-100 (national standard, 50), and compared between the presence and absence of grade 2 or higher edema and between before and after administration of DTX. Twenty patients met the eligibility criteria and were included in the study. There was no difference in the HRQOL score according to whether grade 2 limb edema was present. The median HRQOL summary scores before and after administration of DTX were 51.1 and 50.8 (p=0.763), respectively, for mental health, 52.6 and 49.4 (p=0.005) for physical health, and 38.9 and 37.5 (p=1.000) for role/social health. We found no direct effect of DTX-induced limb edema on HRQOL in patients with early-stage breast cancer. However, HRQOL summary scores indicated that administration of DTX reduced physical health in these patients.

多西他赛(DTX)是乳腺癌围手术期化疗的主要药物。水肿是 DTX 的一种已知不良反应,但其对健康相关 QOL(HRQOL)的影响尚不明确。在这项研究中,我们评估了早期乳腺癌患者因服用 DTX 而导致的水肿对 HRQOL 的影响。我们对 2021 年 9 月至 2022 年 12 月期间在山梨县立中心医院接受 4 个周期 DTX 术前或术后化疗的早期乳腺癌(I-III 期)患者进行了前瞻性调查。每次使用 DTX 时测量每个肢体的周长,并根据不良事件通用术语标准 5.0 版评估肢体水肿情况。HRQOL 采用 SF-12 第 2 版进行评估,其范围为 0-100(国家标准为 50),并对有无 2 级或以上水肿以及服用 DTX 前后进行比较。20 名患者符合资格标准并被纳入研究。是否存在二级肢体水肿对患者的 HRQOL 评分没有影响。服用 DTX 前后的 HRQOL 总分中位数分别为:心理健康 51.1 分和 50.8 分(p=0.763),身体健康 52.6 分和 49.4 分(p=0.005),角色/社会健康 38.9 分和 37.5 分(p=1.000)。我们发现,DTX 引起的肢体水肿对早期乳腺癌患者的 HRQOL 没有直接影响。然而,HRQOL 总分显示,服用 DTX 会降低这些患者的身体健康水平。
{"title":"Effect of Perioperative Docetaxel-induced Limb Edema on Health-related Quality of Life in Patients with Early-stage Breast Cancer: A Prospective Observational Study.","authors":"Kaori Matsumoto, Yoshihito Morimoto, Junichiro Wakatsuki, Daiki Sakuma, Keiko Mukouyama, Masayuki Inoue, Ayako Kimura, Iori Hirosawa, Kazuhiro Watanabe","doi":"10.1248/yakushi.23-00206","DOIUrl":"10.1248/yakushi.23-00206","url":null,"abstract":"<p><p>Docetaxel (DTX) is a key drug used in perioperative chemotherapy for breast cancer. Edema is a known adverse effect of DTX, but its effect on health-related QOL (HRQOL) is unclear. In this study, we evaluated the effects of edema caused by administration of DTX on HRQOL in patients with early-stage breast cancer. We prospectively investigated patients diagnosed with early-stage breast cancer (stage I-III) who received 4 cycles of DTX as preoperative or postoperative chemotherapy between September 2021 and December 2022 at Yamanashi Prefectural Central Hospital. The circumference of each extremity was measured at each administration of DTX, and limb edema was evaluated by Common Terminology Criteria for Adverse Events version 5.0. HRQOL was evaluated using SF-12 version 2, which has a range of 0-100 (national standard, 50), and compared between the presence and absence of grade 2 or higher edema and between before and after administration of DTX. Twenty patients met the eligibility criteria and were included in the study. There was no difference in the HRQOL score according to whether grade 2 limb edema was present. The median HRQOL summary scores before and after administration of DTX were 51.1 and 50.8 (p=0.763), respectively, for mental health, 52.6 and 49.4 (p=0.005) for physical health, and 38.9 and 37.5 (p=1.000) for role/social health. We found no direct effect of DTX-induced limb edema on HRQOL in patients with early-stage breast cancer. However, HRQOL summary scores indicated that administration of DTX reduced physical health in these patients.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141200652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Assessing the Impact of in-Hospital Formulary Policies on the Prescription Patterns of Direct Oral Anticoagulants (DOACs)]. [评估院内处方集政策对直接口服抗凝药(DOACs)处方模式的影响]。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/yakushi.24-00078
Kyohei Yoshida, Go Morikawa, Ken Kubota, Katsuko Okazawa

Prescribing direct oral anticoagulants (DOACs) with off-label dosage and administration is discouraged due to concerns about their effectiveness and safety. Consequently, our hospital pharmacist established a formulary with physicians for oral anticoagulants. Our study aimed to assess the adherence to this formulary by investigating the rate of appropriate DOAC prescribing. We included patients who were newly prescribed or continued on DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) at our hospital. We calculated the percentage of patients prescribed the correct dosage and administration according to the package insert and compared this across three time periods: pre-intervention (period A; April-September 2019), post-intervention phase 1 (period B; August 2021-January 2022), and post-intervention phase 2 (period C; November 2022-April 2023). We also examined the number of inquiries and consultation requests made by hospital pharmacists regarding DOAC dosage and administration. A total of 782 patients were surveyed (191 in period A, 263 in period B, and 328 in period C). The appropriate prescribing rates for DOACs were 79.1% in period A, 84.4% in period B, and 86.6% in period C. The proportion of cases where hospital pharmacists questioned or consulted doctors about DOAC dosage and administration was 3.7% in period A, 6.1% in period B, and 10.1% in period C. These findings indicate that active intervention by hospital pharmacists using the formulary regarding oral anticoagulant formularies may promote appropriate DOAC use.

由于担心直接口服抗凝药(DOAC)的有效性和安全性,我们不鼓励开具标示外剂量和用法的处方。因此,我们医院的药剂师与医生共同制定了口服抗凝药处方集。我们的研究旨在通过调查 DOAC 的适当处方率来评估对该处方集的遵守情况。我们纳入了本医院新开具或继续服用 DOAC(达比加群、利伐沙班、阿哌沙班和依度沙班)的患者。我们计算了根据包装说明书正确处方和用药的患者比例,并在三个时间段进行了比较:干预前(A 阶段;2019 年 4 月至 9 月)、干预后第 1 阶段(B 阶段;2021 年 8 月至 2022 年 1 月)和干预后第 2 阶段(C 阶段;2022 年 11 月至 2023 年 4 月)。我们还调查了医院药剂师就 DOAC 剂量和用药提出的询问和咨询请求的数量。共调查了 782 名患者(A 阶段 191 人,B 阶段 263 人,C 阶段 328 人)。医院药剂师就 DOAC 的剂量和用药向医生提出询问或咨询的比例在 A 期为 3.7%,B 期为 6.1%,C 期为 10.1%。
{"title":"[Assessing the Impact of in-Hospital Formulary Policies on the Prescription Patterns of Direct Oral Anticoagulants (DOACs)].","authors":"Kyohei Yoshida, Go Morikawa, Ken Kubota, Katsuko Okazawa","doi":"10.1248/yakushi.24-00078","DOIUrl":"https://doi.org/10.1248/yakushi.24-00078","url":null,"abstract":"<p><p>Prescribing direct oral anticoagulants (DOACs) with off-label dosage and administration is discouraged due to concerns about their effectiveness and safety. Consequently, our hospital pharmacist established a formulary with physicians for oral anticoagulants. Our study aimed to assess the adherence to this formulary by investigating the rate of appropriate DOAC prescribing. We included patients who were newly prescribed or continued on DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) at our hospital. We calculated the percentage of patients prescribed the correct dosage and administration according to the package insert and compared this across three time periods: pre-intervention (period A; April-September 2019), post-intervention phase 1 (period B; August 2021-January 2022), and post-intervention phase 2 (period C; November 2022-April 2023). We also examined the number of inquiries and consultation requests made by hospital pharmacists regarding DOAC dosage and administration. A total of 782 patients were surveyed (191 in period A, 263 in period B, and 328 in period C). The appropriate prescribing rates for DOACs were 79.1% in period A, 84.4% in period B, and 86.6% in period C. The proportion of cases where hospital pharmacists questioned or consulted doctors about DOAC dosage and administration was 3.7% in period A, 6.1% in period B, and 10.1% in period C. These findings indicate that active intervention by hospital pharmacists using the formulary regarding oral anticoagulant formularies may promote appropriate DOAC use.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Forty-three Years of Dedicated Efforts in Advancing Pharmacist Expertise: Aspiring to Become a Pharmacist and Cultivate Pharmacists Proficient in Recommending Prescription Medicines to Doctors]. [四十三年来致力于提高药剂师的专业知识:立志成为药剂师,培养精通向医生推荐处方药的药剂师]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00193
Hitomi Teramachi

When I graduated from university, my aim was to become a pharmacist capable of recommending prescription medicines to doctors and teaching others to do the same. To achieve this goal, I developed comprehensive curricula incorporating progressive educational tools such as problem-based learning and small group discussions. Subsequently, the effectiveness of these tools and curricula was evaluated, and the findings of these assessments were published in various peer-reviewed journal articles. Consequently, a body of evidence on the most effective ways to recommend prescription medicines to doctors was gradually established. This paper aims to summarize this comprehensive body of research spanning over 43 years, with the objective of highlighting the valuable insights gained thus far, identifying the best practice techniques, and exploring potential avenues for future research.

大学毕业时,我的目标是成为一名药剂师,能够向医生推荐处方药,并教其他人也这样做。为了实现这一目标,我开发了综合课程,其中纳入了基于问题的学习和小组讨论等渐进式教育工具。随后,我对这些工具和课程的有效性进行了评估,评估结果发表在各种同行评审的期刊文章中。因此,关于向医生推荐处方药的最有效方法的证据体系逐渐建立起来。本文旨在对这一跨越 43 年的综合研究进行总结,目的是强调迄今为止获得的宝贵见解,确定最佳实践技术,并探索未来研究的潜在途径。
{"title":"[Forty-three Years of Dedicated Efforts in Advancing Pharmacist Expertise: Aspiring to Become a Pharmacist and Cultivate Pharmacists Proficient in Recommending Prescription Medicines to Doctors].","authors":"Hitomi Teramachi","doi":"10.1248/yakushi.23-00193","DOIUrl":"10.1248/yakushi.23-00193","url":null,"abstract":"<p><p>When I graduated from university, my aim was to become a pharmacist capable of recommending prescription medicines to doctors and teaching others to do the same. To achieve this goal, I developed comprehensive curricula incorporating progressive educational tools such as problem-based learning and small group discussions. Subsequently, the effectiveness of these tools and curricula was evaluated, and the findings of these assessments were published in various peer-reviewed journal articles. Consequently, a body of evidence on the most effective ways to recommend prescription medicines to doctors was gradually established. This paper aims to summarize this comprehensive body of research spanning over 43 years, with the objective of highlighting the valuable insights gained thus far, identifying the best practice techniques, and exploring potential avenues for future research.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Challenges Facing Middle Molecule Drug Discovery and How to Overcome Them]. [中分子药物研发面临的挑战及如何克服这些挑战]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00191-F
Hiroyuki Miyachi, Katsumi Maenaka
{"title":"[Challenges Facing Middle Molecule Drug Discovery and How to Overcome Them].","authors":"Hiroyuki Miyachi, Katsumi Maenaka","doi":"10.1248/yakushi.23-00191-F","DOIUrl":"10.1248/yakushi.23-00191-F","url":null,"abstract":"","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Application of Hydrogenated Soya Lecithin in Solid Dispersion and Oily Gel, and the Study of Skin-Applied Formulations]. [氢化大豆卵磷脂在固体分散体和油性凝胶中的应用及皮肤应用配方研究]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00155
Makiko Fujii

I have been studying the improvement of drug solubility using solid dispersion and skin-applied formulations. When preparing solid dispersions using phosphatidylcoline (PC) as a carrier, drug with hydrogen-donating groups interacts with PC to produce amorphous solid dispersions with high drug content; this overcomes improves drug absorption. The drug was solubilized and supersaturated in the oil-based gel formed with hyadrogenated lecithin; this facilitates drug permeation through the skin. The promoting effect differs with the nature of the oil used because of the skin penetration of the oil itself and the accompanying increase in drug solubility and diffusion coefficient in the skin. At actual application volumes of 10 µL/cm2 or less, the skin penetration of poorly-absorbable drugs depends on the molecular weight and surface tension of the oil. The penetration of the oil vehicle into the upper stratum corneum influences the reach of the drug into the stratum corneum; a high drug concentration near the 7th layer of the stratum corneum promotes migration through the skin by increasing the linear concentration gradient in deeper layers. In addition, we performed a risk assessment, in collaboration with toxicologists, for dermal safety that included the toxicity potential of substances and the parts related to skin transfer.

我一直在研究利用固体分散体和皮肤应用制剂提高药物溶解度的问题。以磷脂酰胆碱(PC)为载体制备固体分散体时,具有氢供体基团的药物会与 PC 相互作用,生成药物含量高的无定形固体分散体,从而改善药物的吸收。药物在用透明卵磷脂形成的油基凝胶中得到溶解和过饱和;这有利于药物通过皮肤的渗透。由于油本身的皮肤渗透性以及随之而来的药物溶解度和在皮肤中的扩散系数的增加,促进作用因所用油的性质而异。在实际用量为 10 µL/cm2 或更小的情况下,吸收性差的药物的皮肤渗透性取决于油的分子量和表面张力。油性载体对上层角质层的渗透影响着药物对角质层的到达;角质层第 7 层附近的高药物浓度会通过增加深层的线性浓度梯度来促进药物在皮肤中的迁移。此外,我们还与毒理学专家合作,对皮肤安全性进行了风险评估,其中包括物质的毒性潜力以及与皮肤转移相关的部分。
{"title":"[Application of Hydrogenated Soya Lecithin in Solid Dispersion and Oily Gel, and the Study of Skin-Applied Formulations].","authors":"Makiko Fujii","doi":"10.1248/yakushi.23-00155","DOIUrl":"10.1248/yakushi.23-00155","url":null,"abstract":"<p><p>I have been studying the improvement of drug solubility using solid dispersion and skin-applied formulations. When preparing solid dispersions using phosphatidylcoline (PC) as a carrier, drug with hydrogen-donating groups interacts with PC to produce amorphous solid dispersions with high drug content; this overcomes improves drug absorption. The drug was solubilized and supersaturated in the oil-based gel formed with hyadrogenated lecithin; this facilitates drug permeation through the skin. The promoting effect differs with the nature of the oil used because of the skin penetration of the oil itself and the accompanying increase in drug solubility and diffusion coefficient in the skin. At actual application volumes of 10 µL/cm<sup>2</sup> or less, the skin penetration of poorly-absorbable drugs depends on the molecular weight and surface tension of the oil. The penetration of the oil vehicle into the upper stratum corneum influences the reach of the drug into the stratum corneum; a high drug concentration near the 7th layer of the stratum corneum promotes migration through the skin by increasing the linear concentration gradient in deeper layers. In addition, we performed a risk assessment, in collaboration with toxicologists, for dermal safety that included the toxicity potential of substances and the parts related to skin transfer.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139088682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1